BELLEROPHON THERAPEUTICS, Inc.
20 Independence Boulevard, Suite 402
Warren, New Jersey 07059
June 8, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jason Drory
Re: Bellerophon Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 2, 2024
File No. 333- 272359 (the “Registration Statement”)
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Bellerophon Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, June 9, 2023, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Jeffrey Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6732 with any questions regarding this request.
| Very truly yours, | ||
| BELLEROPHON THERAPEUTICS, INC. | ||
| /s/ Peter Fernandes | ||
| Peter Fernandes Chief Financial Officer |
cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Jeffrey Schultz, Esq.
